SSL International ousts CEO (chief executive officer) after second profit warning
This article was originally published in Clinica
SSL International has "invited" its CEO to step down in the wake of the company's second profits warning in four months. Speculation about developments at the company had already been heightened following reported disagreements between directors last week and the first of the two profit warnings last November (see Clinica No 946, p 14). Separately, the UK company is also to lose its chairman, Stuart Wallis, who has said he will not renew his contract, which expires at the end of July.
You may also be interested in...
Facing soaring legal costs stemming from its failed merger with Fresenius Kabi and burdened by substantial debt, Akorn elected to put itself up for sale earlier this year in order to help repay lenders. But the company has now defaulted on an agreement with its creditors after no bidder stepped up to the plate.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.